This is a discussion on The direct effects of stored blood products may worsen prognosis of cancer patients within the Medical Articles and Abstracts forum; The direct effects of stored blood products may wo...[Med Hypotheses. 2008] - PubMed Result Med ...
|
|||
|
The direct effects of stored blood products may worsen prognosis of cancer patients
The direct effects of stored blood products may wo...[Med Hypotheses. 2008] - PubMed Result
Med Hypotheses 2008 Jun 28. [Epub ahead of print] The direct effects of stored blood products may worsen prognosis of cancer patients; shall we transfuse or not? An explanation of the adverse oncological consequences of blood product transfusion with a testable hypothesis driven experimental research protocol Upile T, Jerjes W, Sandison A, Singh S, Rhys-Evans P, Sudhoff H, Hopper C. The Ear Institute, University College London, UK; Head and Neck Cancer Unit, University College London Hospital, UK; Department of Head & Neck Surgery, Royal Marsden Hospital, UK. Francis and colleagues reported an association between blood transfusion and worsened cancer prognosis. Since then there has been much debate over whether there is in fact such an association. We propose a possible mechanism which could explain much of the conflicting clinical and experimental evidence, and which can be readily tested experimentally. It is suggested that the extracellular accumulation of bioactive factors in blood transfusion products can directly and indirectly cause tumour growth and hence a worsening of prognosis. This theory can be applied both in vitro and in vivo. Two separate UK studies have shown that perioperative blood transfusion is associated with worsened prognosis in head and neck squamous cell cancer patients. Furthermore, pilot experiments have shown that as blood ages, endothelial growth factors are leached from the metabolically compromised red cell. We believe that we have provided a rationale to explain the conflicting findings of research to date in this area. That red cells should store endothelial reparative growth factors would seem logical, as would the release of any factors as the metabolic processes of the anucleate red cell decline over time. As a result, leuco-depletion should be promoted and blood transfusion should be avoided if possible. PMID: 18590945 [PubMed - as supplied by publisher] |
| The Following User Says Thank You to Informaticus For This Useful Post: | ||
Bob Jordan (08-12-2008) | ||
![]() |
| Tags |
| adverse effects, blood products, cancer, transfusion |
| Currently Active Users Viewing This Thread: 1 (0 members and 1 guests) | |
| Thread Tools | Search this Thread |
| Display Modes | Rate This Thread |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Stem cell therapy offers hope for blood-cancer patients | Jan B. Wade | News and Hot Topics such as Hepatitis C, SARS and AIDS | 0 | 03-06-2008 11:09 AM |
| The use of erythropoietin in patients undergoing radical prostatectomy: effects . . . | Sharon Grant | Medical Articles and Abstracts | 0 | 01-27-2007 10:07 PM |
| Anemia in Patients With Cancer or Undergoing Cancer Therapy: Impact and Current Treat | Jan B. Wade | Medical Articles and Abstracts | 1 | 04-11-2005 12:07 PM |
| Prior red blood cell transfusions in cancer patients increase the risk of subsequent | Nika | Medical Articles and Abstracts | 0 | 04-04-2005 11:15 PM |
| Correlation Between Perioperative Blood Transfusion and Prognosis of Patients | Jan B. Wade | Medical Articles and Abstracts | 0 | 07-17-2003 03:02 PM |